Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dapagliflozin + omega-3 carboxylic acids
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral
01
Overview
Dapagliflozin + omega-3 carboxylic acids is an investigational combination therapy consisting of dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and omega-3 carboxylic acids, a formulation of free fatty acids primarily composed of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Dapagliflozin lowers blood glucose by inhibiting SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion. Omega-3 carboxylic acids exert lipid-lowering effects by reducing hepatic triglyceride synthesis and promoting fatty acid oxidation. The combination has been studied for its potential to reduce liver fat content in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease (NAFLD), showing significant reductions in liver fat compared to monotherapies[1][2][3].
- Other names
- OM-3CA + dapagliflozinOmega-3 carboxylic acids + dapagliflozinEpanova + dapagliflozin
02
Targets
SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on dapagliflozin + omega-3 carboxylic acids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dapagliflozin + omega-3 carboxylic acids.